Fatty acid desaturase

Yumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, May 12, 2022
Death, Inflammation, Risk, Traffic barrier, Company, Disease, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, SCD, Patient, Phospholipid, Alpha-synuclein, Clinical trial, Amyotrophic lateral sclerosis, COVID-19, Muscle atrophy, Neuron, Neurodegeneration, Triglyceride, Industry, Synucleinopathy, Data collection, SREBF1, Cognition, Toxicity, Compte rendu, FTLD, Membrane, ALS, Ester, Movement, Phrase, Neurotoxicity, Fatty acid desaturase, Pharmaceutical industry, Yuman–Cochimí languages

YTX-7739 is Yumanity Therapeutics proprietary lead small molecule investigational therapy designed to penetrate the blood-brain barrier and inhibit the activity of a novel target, stearoyl-CoA desaturase (SCD).

Key Points: 
  • YTX-7739 is Yumanity Therapeutics proprietary lead small molecule investigational therapy designed to penetrate the blood-brain barrier and inhibit the activity of a novel target, stearoyl-CoA desaturase (SCD).
  • The company is assessing the potential utility of YTX-7739 as a disease modifying therapy for Parkinsons disease.
  • SCD is an enzyme that catalyzes fatty acid desaturation, the products of which are incorporated into phospholipids, triglycerides, or cholesterol esters.
  • Yumanity explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Yumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, March 24, 2022
Company, Private Securities Litigation Reform Act, Risk, Amyotrophic lateral sclerosis, Cognition, Neurodegeneration, Synucleinopathy, Traffic barrier, Triglyceride, Death, Clinical trial, Fatty acid desaturase, Phospholipid, ALS, Muscle atrophy, Ester, Alpha-synuclein, FTLD, Neurotoxicity, Membrane, SCD, Industry, Inflammation, Data collection, COVID-19, U.S. Securities and Exchange Commission, SREBF1, Compte rendu, Phrase, Neuron, Movement, Patient, Disease, Toxicity, Pharmaceutical industry, Yuman–Cochimí languages

YTX-7739 is Yumanity Therapeutics proprietary lead small molecule investigational therapy designed to penetrate the blood-brain barrier and inhibit the activity of a novel target, stearoyl-CoA desaturase (SCD).

Key Points: 
  • YTX-7739 is Yumanity Therapeutics proprietary lead small molecule investigational therapy designed to penetrate the blood-brain barrier and inhibit the activity of a novel target, stearoyl-CoA desaturase (SCD).
  • The company is assessing the potential utility of YTX-7739 as a disease modifying therapy for Parkinsons disease.
  • SCD is an enzyme that catalyzes fatty acid desaturation, the products of which are incorporated into phospholipids, triglycerides, or cholesterol esters.
  • Yumanity explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Yumanity Reports Partial Clinical Hold by U.S. FDA on Multidose Clinical Trials for YTX-7739  

Retrieved on: 
Wednesday, January 19, 2022
Neurodegeneration, Patient, SCD, Cognition, Clinical trial, Private Securities Litigation Reform Act, FTLD, Fatty acid desaturase, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neurotoxicity, COVID-19, Safety, Growth, Death, Disease, GLOBE, IND, Movement, U.S. Securities and Exchange Commission, Traffic barrier, Industry, Therapy, Phrase, Company, ALS, Data collection, Neuron, Toxicity, Risk, Food, Muscle atrophy, Compte rendu, FDA, Trial of the century, Amyotrophic lateral sclerosis, Pharmaceutical industry, Yuman–Cochimí languages

The FDA has not halted all clinical programming and is permitting the Companys planned single dose clinical trial to proceed.

Key Points: 
  • The FDA has not halted all clinical programming and is permitting the Companys planned single dose clinical trial to proceed.
  • The partial clinical hold suspends initiation of multiple dose clinical trials in the U.S. until the FDAs questions have been addressed.
  • Yumanity anticipates working closely with the FDA to adequately address their concerns.
  • Yumanity Therapeutics explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Yumanity’s Approach to Neurodegenerative Diseases Validated by Two External Collaborations

Retrieved on: 
Tuesday, January 11, 2022
Neurodegeneration, Research, Patient, Clinical trial, FTLD, Private Securities Litigation Reform Act, Fatty acid desaturase, COVID-19, Safety, Achievement, Growth, The Michael J. Fox Foundation, GLOBE, U.S. Securities and Exchange Commission, Traffic barrier, Industry, MJFF, Therapy, Phrase, Company, ALS, Translation, Data collection, Toxicity, Risk, Muscle atrophy, Translational research, Compte rendu, Amyotrophic lateral sclerosis, Pharmaceutical industry, Yuman–Cochimí languages, Merck

BOSTON, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease, today provided an update on recent corporate developments. This includes the achievement of a research milestone for our joint amyotrophic lateral sclerosis (ALS) / frontotemporal lobar dementia (FTLD) program, which triggered a $5 million milestone payment to Yumanity from Merck and the awarding of a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to accelerate early proof-of-concept testing of a promising Parkinson’s disease therapy.

Key Points: 
  • Our target discovery engine is designed to reveal these processes and identify targets for therapeutic intervention.
  • We are very gratified to further validate the strength of our platform through our collaborations with Merck and the Michael J.
  • Yumanity Therapeuticsis a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform.
  • Yumanitys drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases.

Yumanity Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

Retrieved on: 
Monday, November 15, 2021
Traffic barrier, Cognition, Phospholipid, Neurodegeneration, FTLD, Safety, Neuron, Membrane, SCD, Industry, Private Securities Litigation Reform Act, Yuman–Cochimí languages, Clinical trial, Alpha-synuclein, Movement, Security (finance), Compte rendu, Disease, Ester, Inflammation, Growth, ALS, Phrase, Muscle atrophy, Amyotrophic lateral sclerosis, Triglyceride, Company, U.S. Securities and Exchange Commission, SREBF1, Toxicity, Death, Synucleinopathy, Neurotoxicity, Patient, Risk, Fatty acid desaturase, Data collection, Pharmaceutical industry

BOSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2021 and provided an overview of the Company’s recent corporate developments and upcoming milestones.

Key Points: 
  • The company is assessing the potential utility of YTX-7739 as a disease modifying therapy for Parkinsons disease.
  • SCD is an enzyme that catalyzes fatty acid desaturation, the products of which are incorporated into phospholipids, triglycerides, or cholesterol esters.
  • Results in preclinical or early-stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval.
  • Yumanity explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Yumanity Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, August 12, 2021
Neurodegeneration, SREBF1, Inflammation, U.S. Securities and Exchange Commission, Triglyceride, Compte rendu, Membrane, Clinical trial, FTLD, Company, Fatty acid desaturase, Movement, Private Securities Litigation Reform Act, Disease, Neuron, Death, Synucleinopathy, Phrase, Risk, Amyotrophic lateral sclerosis, Alpha-synuclein, Toxicity, Cognition, Security (finance), Patient, ALS, Growth, Muscle atrophy, SCD, Data collection, Safety, Neurotoxicity, Industry, Yuman–Cochimí languages, Traffic barrier, Ester, Phospholipid, Pharmaceutical industry

BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2021, and provided an overview of the Company’s recent corporate developments and upcoming milestones.

Key Points: 
  • The company is assessing the potential utility of YTX-7739 as a disease modifying therapy for Parkinsons disease.
  • SCD is an enzyme that catalyzes fatty acid desaturation, the products of which are incorporated into phospholipids, triglycerides, or cholesterol esters.
  • Results in preclinical or early-stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval.
  • Yumanity explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Yumanity Therapeutics Announces Study Demonstrating In Vivo Efficacy of YTX-7739 in a Glioblastoma Multiforme (GBM) Mouse Model

Retrieved on: 
Tuesday, April 6, 2021
Branches of biology, Enzymes, Fatty acid desaturase, Stearoyl-CoA desaturase-1, Scd, Stearoyl-CoA, Biology, Small molecule, Very-long-chain 3-oxoacyl-CoA synthase

YTX-7739 is currently in clinical development by Yumanity Therapeutics as a potential treatment for Parkinsons disease.

Key Points: 
  • YTX-7739 is currently in clinical development by Yumanity Therapeutics as a potential treatment for Parkinsons disease.
  • They had recently shown that GBM cancer stem cells are highly susceptible to pharmacological permutation of stearoyl-CoA desaturase (SCD).
  • YTX-7739 is Yumanity Therapeutics proprietary lead small molecule investigational therapy designed to penetrate the blood-brain barrier and inhibit the activity of a novel target, stearoyl-CoA desaturase (SCD).
  • Yumanity Therapeutics explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.